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Abstract 
Purpose: To determine the effect of three calmodulin antagonists (A-7, W-7 and W-13) on the 
subpopulations of CD44/CD24 immunophenotypes in MDA-MB-231 and MDA-MB-468 breast cancer 
cell lines.  
Methods: Flow cytometry analysis was used to determine the proportion of the various subpopulations 
of the immunophenotypes, viz, CD44+CD24-, CD44-CD24+ and CD44+CD24+, when MDA-MB-231 
and MDA-MB-468 cells were subjected to calmodulin antagonists. The effect of W-13 on the invasion 
properties of MDA-MB-231 and MDA-MB-468 was investigated using Matrigel invasion assay.  
Results: A-7, W-7 and W-13 caused alterations in the subpopulation of CD44+CD24- in MDA-MB-231 
cells. The most potent antagonist was W-13 as it reduced the proportion of tumorigenic CD44+CD24- to 
0.64 ± 0.05 at a concentration of 80 µM. In contrast, the subpopulation of MDA-MB-468 cells, which had 
a low fraction of CD44+CD24-, was not altered when administered with W-7 but showed variations 
when incubated with W-13. Specifically, when the concentration of W-13 increased from 20 – 100 µM, 
the proportion of CD44+CD24+ was reduced from 92.93 ± 3.2 to 60.96 ± 2.4.  The effect of W-13 on the 
subpopulations of CD44+CD24- and CD44+CD24+ in MDA-MB-231 and MDA-MB-468, respectively, 
reduced the invasion properties of the cells.    
Conclusion: The calmodulin antagonist, W-13, has a significant antitumor effect on MDA-MB-231 and 
MDA-MB-468 breast cancer cells. 
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Breast cancer cells have been reported to 
contain more than one immunophenotype 
subpopulations that have different invasive 
properties and roles in tumorigenicity [1,2]. They 
were distinguished according to the expression 
level of two glycoproteins on the surface of the 
cells, CD44 and CD24, markers of breast cancer 
cell phenotype since CD44 binds E‐selectin and 
CD24 is known to be attached to P‐selectin [3,4]. 
Cells with high levels of CD44 and low level of 
CD24 (CD44 + CD24-) were identified as cancer 
stem cells that have the ability to self‐renew and 
differentiate. In spite of the arguable clinical 
significance of CD44+CD24-, they have been 
associated with distant metastasis and 
unfortunate survival [5].  
Wali et al 
Trop J Pharm Res, August 2015; 14(8): 1394  
 
CD44 is a ubiquitous multi-structural and multi-
functional cell surface glycoprotein involved in 
adhesive cell-cell and cell-matrix interactions, 
and cell migration and cell homing. 
 
A previous study reported that by ectopically 
overexpressing a splice variant of CD44, it was 
enough for a non-metastatic rat glioma cell line to 
attain metastatic properties [6]. The variant 
isoforms of CD44 have showed antiproliferative 
and apoptotic effect [7,8].   
 
While CD44 is associated with stem cell-like 
cancer cells, CD24 is correlated with either 
luminal or basal breast cancer cells [9]. In the 
presence of high proportions of CD24+, the 
luminal cells are likely to exist whereas the basal 
cells are expressed at higher percentages of 
CD24-.   
 
Several compounds have been tested for 
inhibiting CD44 such as the calcium-modulated 
protein (calmodulin) antagonists (chlorpro-
mazine, trifluoperazine, W-7) and the calcium 
blocker verapamil [10]. However, the study did 
not test the effect of these compounds on breast 
cancer stem cells. It is not known, however, 
whether targeting CD44 can alter the fate of 
cancer stem cells themselves. In this study, the 
effect of the calmodulin antagonists (N-(10-
Aminodecyl)-5-chloro-1-naphthalenesulfonamide 
hydrochloride (A-7), N-(6-Aminohexyl)-5-chloro-
1-naphthalenesulfonamide hydrochloride (W-7) 
and N-(4-Aminobutyl)-5-chloro-2-naphthalene-
sulfonamide hydrochloride (W-13)) on MDA-MB-
231 and MDA-MB-468 breast cancer cell lines 




Materials and cell lines  
 
Monoclonal antibodies against human CD44 
(FITC; cat. #555478) and CD24 (PE; cat. 
#555428) were obtained from BD Biosciences 
(San Diego, CA, USA). The breast cancer cell 
lines (MDA-MB-231 and MDA-MB-468) were 
obtained from American Type Tissue Culture 
Collection (Manassas, VA, USA).  
 
Flow cytometric analysis of cancer stem cells 
subjected to A-7, W-7 and W-13 
 
Cells were cultured and incubated in different 
concentrations of A-7, W-7 and W-13 for 24 
hours as described elsewhere [11]. Cells were 
washed once with phosphate-buffered saline 
(PBS) and then harvested with 0.05 % 
trypsin/0.025 % ethylenediaminetetraacetic acid 
(EDTA). Detached cells were washed with PBS 
containing 1 % fetal calf serum and 1 % 
penicillin/streptomycin (washing buffer), and re-
suspended in the wash buffer (106 cells/100 μL). 
Combinations of fluorochrome-conjugated 
monoclonal antibodies against human CD44 and 
CD24 or their respective isotype controls were 
added to the cell suspension at concentrations 
recommended by the manufacturer and 
incubated at 4 °C in the dark for 30 to 40 min. 
The labeled cells were washed in the wash 
buffer, and then were analyzed using the flow 
cytometry.  
 
Matrigel invasion assay 
 
The invasion assay was performed as 
recommended by the manufacturer of the 
invasion assay kit (#ECM554; Chemicon 
International, Temecula, CA, USA). Briefly, cells 
were serum starved and incubated for 24 h. The 
50,000 cells were placed on the top insert with 
matrigel. Serum-free media supplemented with 
several concentrations of W-13 or media with 10 
% serum was placed in the bottom well. After 24 
h, the number of cells that invaded through the 
matrigel were calculated using fluorometric 
assay. For each cell line, the fluorometric reading 
from bottom wells with the serum-free media was 
defined as one unit to determine relative change 
in invasion in the presence of 10 % serum. Each 
experiment contained one or two wells without 
serum and two wells with serum for each cell 
line. The experiment was repeated twice for 




Data were represented as mean ± standard 
deviation ( ). Statistical analysis was carried out 
with one-way analysis of variance (ANOVA) and 
difference between groups was considered 




Effect of A-7, W-7 and W-13 on CD44/CD24 
immunophenotypic subpopulations of  
MDA-MB-231 and MDA-MB-468 
 
As shown in Figure 1, all calmodulin antagonists 
(A-7, W-7 and W-13) caused alterations in the 
subpopulation of the phonotypic CD44 + CD24- 
of MDA-MB-231 cells. At lower concentrations 
(20 µM), the percentages of the CD44 + CD24- 
subpopulation were similar when subjected into 
the calmodulin antagonists of A-7, W-7 and W-13 
as they were 75.36 ± 2.34, 65.44 ± 7.5 and 61.47 
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± 4.9, respectively.  However, when the 
concentrations of the antagonists were 
increased, there were some discrepancies in the 
percentages of the subpopulation of 
CD44+CD24-cells. As displayed in Figure 1a, the 
antagonist, A-7, caused reduction in the 
percentages of the expressed CD44+CD24- from 
75.36 ± 2.34 to 38.63 ± 5.7 when the 
concentration of A-7 was enhanced from 20 to 60 
µM but the percentages of CD44+CD24- 
increased to 79.76 ± 3.4 and 77.97 ± 5.6 when 
the concentration was increased into 80 and 100 
µM, respectively.  
 
On the other hand, both of W-7 and W-13 have 
caused reduction in the percentages of the 
expressed CD44+CD24- cells as their 
concentration increased from 20 to 100 µM 
(Figures 1b and 1c). The antagonist, W-13, was 
more potent than W-7 as the percentages of 
CD44+CD24- cells were considerably reduced at 
different concentrations (40 -100 µM) compared 
to W-7. At 100 µM, W-7 and W-13 reduced the 
proportion of CD44 + CD24- to 30.27 and 0.44, 
respectively.   
 
Furthermore, the effect of W-7 and W-13 on 
CD44/CD24 immunophenotypic subpopulations 
of MDA-MB-468 cells was determined. It was 
observed that the expression of CD44+CD24- 
when subjected to different concentrations of W-
7 (20 -100 µM) was zero and most of the 
expressed cells were the luminal CD44+CD24+ 
with a percentage of 99.54 ± 0.12 whereas the 
percentages of the CD44-CD24+ were in the 
range of 0.37-0.66. In contrast, the MDA-MB-468 
cells administered different concentrations of W-
13 revealed that the percentages of 
CD44+CD24- did not significantly differ as they 
were in the range of 0.1-0.27 (Figure 2). 
Interestingly, as the concentration of W-13 
increased, the percentages of the subpopulations 
of CD44+CD24+ decreased whereas the 







Figure 1: Effect of the calmodulin antagonists, (a) A-7, (b) W-7 and (c) W-13, on the subpopulations expression 
of the immunophenotype (-●-)CD44+/CD24-, (-□-) CD44+CD24+ and (-▲-) CD44-CD24+ of MDA-MB-231 cells  
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Figure 2: Effect of W-13 on the subpopulations expression of the immunophenotype (-●-) CD44+/CD24-, (-□-) 
CD44+CD24+ and (-▲-) CD44-CD24+ of MDA-MB-468a 
 
Effect of W-13 on the invasive properties of 
CD44+CD24- of MDA-MB-231 and MDA-MB-
468 cells 
 
Based on flow cytometry analysis, W-13 had a 
potential effect on the proportion of CD44+CD24- 
of MDA-MB-231 and caused significant 
alterations in the subpopulation of CD44CD24 
immunophenotypes of MDA-MB-468. As a 
consequence, further studies on the W-13 effect 
on the invasive properties of MDA-MB- 231 and 
MDA-MB-468 were made. In Figure 3, the 
concentration of W-13 was plotted against the 
mean relative fluorescence unit which correlated 
to the invasion properties of the cells. The 
invasion properties of MDA-MB-231 and MDA-
MB-468 cells were reduced as the 
concentrations of W-13 increased. However, the 
mean relative fluorescence units of MDA-MB-231 
at all concentrations of W-13 were significantly 




Calmodulin antagonists have antitumor activities 
against various cancers which could be 
explained by the role of calmodulin in raising the 
rate of cell growth and degree of tumor 
malignancy [12].  For example, W-7 has 
antiproliferative effect against skin cancer [13] 
and has the potential to suppress the expression 
of the MTS1 and NM23 genes in highly 
metastatic murine melanoma cells [14]. The 
anticancer effect of calmodulin antagonists could 
be due to impeding protein synthesis [15], 





Figure 3: Effect of W-13 on the invasive properties of (-●-)MDA-MB-231 and (-□-) MDA-MB-468 cells 
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In 2003, Al-Hajj et al [1] were able to discriminate 
breast cancer cells based on their cell surface 
marker expression. They demonstrated that the 
cancer cells with the immunophenotype, 
CD44+CD24-, were able to initiate tumor 
whereas other phenotype populations, 
CD44+CD24+, CD44-CD24+, were non-
tumorigenic cancer cells. In this study, 
calmodulin antagonists, A-7, W-7 and W-13, 
were subjected MDA-MB-231 breast cancer cells 
in order to look for their effect on the proportions 
of the immunophenotype subpopulations of the 
breast cancer cells.  Based on flow cytometry 
analysis, it has been found that W-13 has the 
greatest inhibition effect on the expression of 
CD44+CD24-. In particular, 80 µM of W-13 was 
sufficient to reduce the proportion of 
CD44+CD24- from 61.47 ± 4.9 to 0.64± 0.05 %. 
Furthermore,   increasing the concentration of W-
13 lowered the proportion of the phenotype  
CD44+CD24+ and enhanced the proportion of 
CD44-CD24+ in MDA-MB-468 cells which 
resulted in reducing the invasive properties of the 
cells. Meyer et al [18] found that CD44+CD24+ 
cause local invasion by stimulating the 
expression of CD44+CD24- while CD44-CD24+ 
does not have effect on the metastatic  




Among the selected calmodulin antagonists, W-
13 had the greatest antitumor effect in both 
MDA-MB-231 and MDA-MB-468 cells. As the 
concentration of W-13 increased, the proportion 
of CD44+CD24- in MDA-MB-231 significantly 
diminished whereas the proportion of 
CD44+CD24+ in MDA-MB-468 cells reduced. 
These alterations in the proportion of the 
subpopulations of CD44/CD24 immunopheno-
types are consistent with the suppression of the 
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